Using all genes in two signatures of ERBB2 and EGFR activation [1,3] to infer pathway activity in a large set of breast tumour samples and using either Spearman or Pearson correlations showed that predicted ERBB2 activity was not highest in the intrinsic HER2+ subtype, and similarly that EGFR activity was not highest in the basal subtype (Additional file 3). The gene discussed is ERBB2; the disease is breast neoplasm.